| Name | Title | Contact Details |
|---|
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.
EpiCeram® Controlled Release Skin Barrier Emulsion is a leading prescription product that has the ability to help repair and heal the skin barrier through a unique mode-of-action different from other medications and eczema treatments. Only EpiCeram® co...
Established in August 1994, Bracco Diagnostics Inc. develops and markets a wide range of diagnostic imaging agents in the U.S. Bracco products are currently used in conjunction with X-ray, CT, MRI, and nuclear medicine. Bracco Diagnostics Inc. is a
Kyowa Kirin is a global specialty pharmaceutical company that applies state-of-the-art biotechnologies to discover and deliver novel medicines. We work on some of the hardest to treat diseases where need is high, and potential for life-changing impact is possible.
Monticello Drug Company is a Jacksonville, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.